Filtered By:
Source: Europace
Condition: Bleeding

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Data on procedural handling and complications of pulmonary vein isolation using the pulmonary vein ablation catheter GOLD(R)
Conclusion The PVAC GOLD® seems to have an acceptable safety profile. The handling is comparable with the previous generation PVAC®.
Source: Europace - May 24, 2016 Category: Cardiology Authors: Leitz, P., Güner, F., Wasmer, K., Foraita, P., Pott, C., Dechering, D. G., Zellerhoff, S., Kochhäuser, S., Lange, P. S., Eckardt, L., Mönnig, G. Tags: Ablation for atrial fibrillation Source Type: research

Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis
ConclusionThe use of real-time 2D ultrasound guidance for femoral vein cannulation decreases access-related bleeding rates and life-threatening vascular complications.
Source: Europace - May 20, 2016 Category: Cardiology Source Type: research

Cost effectiveness of LAA closure in patients with AF and contraindications to warfarin: comment
This study evaluated the costs of percutaneous left atrial appendage closure (LAAC) using the Watchman device (Boston Scientific, Marlborough, MA). As pointed out by the authors, procedures to implement percutaneous devices are associated with a 6.7% short-term risk of major complications (air embolism, major bleeding, and pericardial effusion). Moreover, the device and technical platform necessary for the procedure come at a significant cost (€9136). Despite these downsides, assuming a willingness-to-pay threshold of€30 000 per quality-adjusted life-year gained, the authors found that relative to both aspirin and apix...
Source: Europace - May 18, 2016 Category: Cardiology Source Type: research

Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings
Conclusion In a nationwide cohort of non-valvular AF patients, outpatients were much more likely to receive OAC therapy and had a significantly lower risk of stroke/TE compared with inpatients and ED patients. However, across all settings investigated, OAC therapy was far from optimal.
Source: Europace - May 11, 2016 Category: Cardiology Authors: Mikkelsen, A. P., Hansen, M. L., Olesen, J. B., Hvidtfeldt, M. W., Karasoy, D., Husted, S., Johnsen, S. P., Brandes, A., Gislason, G., Torp-Pedersen, C., Lamberts, M. Tags: Atrial fibrillation Source Type: research

Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry
Conclusion Even in this cohort with high overall rates of oral anticoagulation use, ESC guideline-adherent antithrombotic management is associated with significantly better outcomes, including those related to mortality and TE, as well as the composite endpoint of ‘cardiovascular death, any TE or bleeding’. These contemporary observations emphasize the importance of guideline implementation, and adherence to the 2012 ESC guidelines for stroke prevention in AF.
Source: Europace - January 4, 2016 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Popescu, M. I., Rasmussen, L. H., Vitali-Serdoz, L., Dan, G.-A., Kalarus, Z., Crijns, H. J. G. M., Oliveira, M. M., Tavazzi, L., Maggioni, A. P., Boriani, G. Tags: Atrial fibrillation Source Type: research

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625–51; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094–106]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an ...
Source: Europace - October 23, 2015 Category: Cardiology Authors: Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P., Advisors:, Ahmad, Heinrich-Nols, Hess, Muller, Munzel, Schwertfeger, Van Eickels, Richard-Lordereau, Document reviewers:, L Tags: EHRA PRACTICAL GUIDE Source Type: research

Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation
Conclusions The combination of CA and percutaneous LAAC in a single procedure is technically feasible in patients with symptomatic drug-refractory AF, high risk of stroke, and contraindications to OACs, although it is associated with a significant risk of major complications.
Source: Europace - October 23, 2015 Category: Cardiology Authors: Calvo, N., Salterain, N., Arguedas, H., Macias, A., Esteban, A., Garcia de Yebenes, M., Gavira, J. J., Barba, J., Garcia-Bolao, I. Tags: Ablation for atrial fibrillation Source Type: research

Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey
The purpose of this European Heart Rhythm Association Survey was to assess the clinical practice in relation to the use of oral anticoagulation therapy for patients with atrial fibrillation (AF) in Europe. Of special interest were patients undergoing percutaneous coronary intervention (PCI), cardioversion procedures, catheter ablation, surgery, and those suffering from anticoagulation-related bleeding. Of 38 responding centres, non-vitamin K antagonist oral anticoagulants (NOACs) were used for stroke prophylaxis and were preferred (33.3%) or considered equal (48.5%) to vitamin K antagonists (VKAs). Only 3% did not use NOAC...
Source: Europace - April 29, 2015 Category: Cardiology Authors: Larsen, T. B., Potpara, T., Dagres, N., Proclemer, A., Sciarrafia, E., Blomstrom-Lundqvist, C., Scientific Initiative Committee, European Heart Rhythm Association, Scientific Initiative Committee, European Heart Rhythm Association, Blomstrom-Lundqvist, Bo Tags: EP WIRE Source Type: research

Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry
Conclusion Our data indicate that overall persistence with rivaroxaban therapy is high, with a discontinuation rate of ~15% in the first year of treatment and few additional discontinuations thereafter.
Source: Europace - April 1, 2015 Category: Cardiology Authors: Beyer-Westendorf, J., Forster, K., Ebertz, F., Gelbricht, V., Schreier, T., Gobelt, M., Michalski, F., Endig, H., Sahin, K., Tittl, L., Weiss, N. Tags: Atrial fibrillation Source Type: research

How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey
This European Heart Rhythm (EHRA) Scientific Initiatives Committee EP Wire Survey aimed at exploring the common practices in approaching patients with atrial fibrillation (AF) and informing them about their risk profiles and available therapies in Europe. In the majority of 53 responding centres, patients were seen by cardiologists (86.8%) or arrhythmologists (64.2%). First- and follow-up visits most commonly lasted 21–30 and 11–20 min (41.5 and 69.8% of centres, respectively). In most centres (80.2%) stroke and bleeding risk had the highest priority for discussion with AF patients; 50.9% of centres had a struc...
Source: Europace - February 26, 2015 Category: Cardiology Authors: Potpara, T. S., Pison, L., Larsen, T. B., Estner, H., Madrid, A., Blomstrom-Lundqvist, C., Conducted by the Scientific Initiatives Committee, and European Heart Rhythm Association, Conducted by the Scientific Initiatives Committee, and European Heart Rhyt Tags: EP WIRE Source Type: research

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013
Conclusion Among oral anticoagulation-naïve AF patients initiated on oral anticoagulation in Denmark, warfarin initiation has declined since the introduction of dabigatran in August 2011. Dabigatran is the most frequently used alternative option to warfarin; however, use of rivaroxaban and apixaban is increasing. Patients initiated with rivaroxaban or apixaban in general have a higher predicted stroke and bleeding risks compared with warfarin or dabigatran initiators.
Source: Europace - January 29, 2015 Category: Cardiology Authors: Olesen, J. B., Sorensen, R., Hansen, M. L., Lamberts, M., Weeke, P., Mikkelsen, A. P., Kober, L., Gislason, G. H., Torp-Pedersen, C., Fosbol, E. L. Tags: Atrial fibrillation Source Type: research

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
Conclusion Using interrupted OAC, low target intraprocedural ACT, and irrigated-tip RF, the rate of peri-procedural groin, haemorrhagic, and thromboembolic complications was extremely low. There were only minimal differences between OACs. Low-risk patients may remain on aspirin/no OAC pre-ablation. There are no problems changing from one OAC pre-ablation to another post-ablation.
Source: Europace - September 29, 2014 Category: Cardiology Authors: Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., Patrawala, R. A. Tags: Ablation for atrial fibrillation Source Type: research

The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation
Conclusion The majority of LAAC costs are borne in the first year, while costs for pharmaceutical strategies continue to accrue year on year. Thus, LAAC represents an opportunity for savings to healthcare systems in the long term. This is an important consideration for payers in evaluating lifetime treatment strategies in AF.
Source: Europace - July 29, 2014 Category: Cardiology Authors: Amorosi, S. L., Armstrong, S., Da Deppo, L., Garfield, S., Stein, K. Tags: Atrial fibrillation Source Type: research

Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion
This article is a summary of the Third Global Summit on LAA occlusion, 15 March 2013, Barcelona, Spain.
Source: Europace - May 5, 2014 Category: Cardiology Authors: Lewalter, T., Kanagaratnam, P., Schmidt, B., Rosenqvist, M., Nielsen-Kudsk, J. E., Ibrahim, R., Albers, B. A., Camm, A. J. Tags: REVIEW Source Type: research

Atrial fibrillation patients do not benefit from acetylsalicylic acid
Conclusion Acetylsalicylic acid as monotherapy in stroke prevention of atrial fibrillation has no discernable protective effect against stroke, and may even increase the risk of ischaemic stroke in elderly patients. Thus, our data support the new European guidelines recommendation that ASA as monotherapy should not be used as stroke prevention in atrial fibrillation.
Source: Europace - May 5, 2014 Category: Cardiology Authors: Sjalander, S., Sjalander, A., Svensson, P. J., Friberg, L. Tags: Atrial fibrillation Source Type: research